South Asians produce 45% more GLP-1 than other populations. Yet still get diabetes earlier. That paradox changes everything. The body isn't listening...suggesting possible GLP-1 resistance. Think of it like screaming in a loud room. Your gut is screaming louder and louder to get your pancreas to respond...but the message isn't getting through. This changes everything about how we think about GLP-1 medications for our community. For most people, GLP-1 RAs are a weight loss drug. For South Asians, it's closer to a metabolic corrector, one that targets the exact bottlenecks in our phenotype. Here's what it actually does in SA phenotypes: - Rests the beta-cells (our pancreas is already a smaller tank, older drugs like sulfonylureas whip it harder until it collapses) - Targets visceral fat specifically (the ectopic fat clogging our liver and pancreas, improving the thin-fat phenotype) - De-clogs the liver with significant improvement in MASLD (aka fatty liver disease) prominent in SAs - Protects blood vessels via endothelial repair (we have some of the highest rates of premature heart disease on earth) This isn't about vanity. It's about catching the mismatch before it becomes a diagnosis. Too often, we wait for the crash, the heart attack, the A1c that finally crosses 6.5, the kidney labs that come back wrong. By then you're managing damage, not preventing it. Correcting a biologically entrenched resistance isn't weakness. It's no different than wearing glasses for poor eyesight. The full deep dive is on Zinda this week → https://open.substack.com/pub/grasshoppermed/p/glp-1-and-south-asian-health?utm_campaign=post-expanded-share&utm_medium=web